Cumhur Tekin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cumhur Tekin has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Bradley Monk
Florida Cancer Specialists and Research Institute, West Palm Beach, FL, USA
3 shared publications - Domenica Lorusso
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy
2 shared publications - Nicoletta Colombo
Gynecologic Oncology Program, European Institute of Oncology, IRCCS, Milan, Italy
2 shared publications A. Arkhipov
(4)Oncology and Chemical Therapy, Medical Rehabilitation Center under the Ministry of Health of Russian Federation, Moscow, Russian Federation
1 shared publicationC. Dubot
Département d'Oncologie Médicale, Institut Curie Saint Cloud, and GINECO, Paris, France
1 shared publication- Changxia Shao
Merck & Co., Inc., Rahway, NJ 07065, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 36 (4) , e110
Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis
Kim YM, et al. J Gynecol Oncol. 2025 Apr;36:e110. https://doi.org/10.3802/jgo.2025.36.e110
- 1 January 2025
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 36 (4) , e110
Open AccessPembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis
Kim YM, et al. J Gynecol Oncol. 2025 Apr;36:e110. https://doi.org/10.3802/jgo.2025.36.e110
- Open Access
- 5 November 2024
- Published by Springer Nature in Oncology and Therapy
- Vol. 13 (1) , 85-98
Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States
Introduction First-line treatment of persistent, recurrent, or metastatic (advanced) cervical cancer in patients who have a combined positive score (CPS) ≥ 1 with pembrolizumab + chemotherapy versus standard-of-care chemotherapy provides meaningful improvements in overall survival. We conducted a cost-effectiveness analysis from a US payer perspective. A societal perspective scenario was also considered, including productivity gains. Methods The cost-effectiveness of pembrolizumab + chemotherapy versus chemotherapy was assessed using a state-transition model comprising the health states “pre-progression,” “post-progression,” and “death,” with a 1-week cycle length and 50-year time horizon. Patient-level KEYNOTE-826 data informed the efficacy, safety, and health-related quality of life of pembrolizumab + chemotherapy versus chemotherapy at first-line and subsequent treatments. Real-world data were sought to cost subsequent treatments according to US clinical practice. Transition probabilities were derived from parametric survival models fit to time-to-progression, progression-free survival, and post-progression survival patient-level KEYNOTE-826 data. Sensitivity analyses explored the impact on outcomes from variables such as bevacizumab use. Results According to the state-transition model, pembrolizumab + chemotherapy extended mean life expectancy versus chemotherapy from 1.8 to 6.7 life-years. The mean gain of 4.9 life-years/patient was mostly caused by pembrolizumab delaying progression. Total discounted quality-adjusted life-years (QALY) were 5.0 and 1.3 per patient for pembrolizumab + chemotherapy and chemotherapy, respectively (mean gain: 3.7 QALY/patient). Pembrolizumab + chemotherapy had comparable safety outcomes to chemotherapy alone. Total costs incurred were US $320,247 (pembrolizumab + chemotherapy) versus US $105,446 (chemotherapy; mean incremental costs: US $214,801/patient). The incremental cost-effectiveness ratio of pembrolizumab + chemotherapy versus chemotherapy was US $58,446/QALY. Sensitivity analyses showed results were insensitive to bevacizumab use. Including productivity gains led to an incremental cost-effectiveness ratio of US $58,385 per QALY. Conclusions Our model-based analysis suggests that first-line treatment of pembrolizumab + chemotherapy in advanced cervical cancer with a CPS ≥ 1 offers a substantial clinical benefit over standard-of-care chemotherapy alone and is cost-effective at a willingness-to-pay threshold of US $150,000. The approximate doubling of life-years and QALYs associated with pembrolizumab + chemotherapy represents a step improvement in the treatment of advanced cervical cancer. Trial Registration ClinicalTrials.gov Identification Number: NCT03635567.
- 5 November 2024
- Published by Springer Nature in Oncology and Therapy
- Vol. 13 (1) , 85-98
Open AccessCost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States
Introduction First-line treatment of persistent, recurrent, or metastatic (advanced) cervical cancer in patients who have a combined positive score (CPS) ≥ 1 with pembrolizumab + chemotherapy versus standard-of-care chemotherapy provides meaningful improvements in overall survival. We conducted a cost-effectiveness analysis from a US payer perspective. A societal perspective scenario was also considered, including productivity gains. Methods The cost-effectiveness of pembrolizumab + chemotherapy versus chemotherapy was assessed using a state-transition model comprising the health states “pre-progression,” “post-progression,” and “death,” with a 1-week cycle length and 50-year time horizon. Patient-level KEYNOTE-826 data informed the efficacy, safety, and health-related quality of life of pembrolizumab + chemotherapy versus chemotherapy at first-line and subsequent treatments. Real-world data were sought to cost subsequent treatments according to US clinical practice. Transition probabilities were derived from parametric survival models fit to time-to-progression, progression-free survival, and post-progression survival patient-level KEYNOTE-826 data. Sensitivity analyses explored the impact on outcomes from variables such as bevacizumab use. Results According to the state-transition model, pembrolizumab + chemotherapy extended mean life expectancy versus chemotherapy from 1.8 to 6.7 life-years. The mean gain of 4.9 life-years/patient was mostly caused by pembrolizumab delaying progression. Total discounted quality-adjusted life-years (QALY) were 5.0 and 1.3 per patient for pembrolizumab + chemotherapy and chemotherapy, respectively (mean gain: 3.7 QALY/patient). Pembrolizumab + chemotherapy had comparable safety outcomes to chemotherapy alone. Total costs incurred were US $320,247 (pembrolizumab + chemotherapy) versus US $105,446 (chemotherapy; mean incremental costs: US $214,801/patient). The incremental cost-effectiveness ratio of pembrolizumab + chemotherapy versus chemotherapy was US $58,446/QALY. Sensitivity analyses showed results were insensitive to bevacizumab use. Including productivity gains led to an incremental cost-effectiveness ratio of US $58,385 per QALY. Conclusions Our model-based analysis suggests that first-line treatment of pembrolizumab + chemotherapy in advanced cervical cancer with a CPS ≥ 1 offers a substantial clinical benefit over standard-of-care chemotherapy alone and is cost-effective at a willingness-to-pay threshold of US $150,000. The approximate doubling of life-years and QALYs associated with pembrolizumab + chemotherapy represents a step improvement in the treatment of advanced cervical cancer. Trial Registration ClinicalTrials.gov Identification Number: NCT03635567.
- Open Access
- 10 October 2024
- Published by Elsevier in Annals of Oncology
- Vol. 36 (1) , 65-75
Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study
- 10 October 2024
- Published by Elsevier in Annals of Oncology
- Vol. 36 (1) , 65-75
Open AccessPembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study
- Open Access
- 1 January 2024
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 35 (6)
Prevalence and prognostic value of PD-L1 expression and tumor mutational burden in persistent, recurrent, or metastatic cervical cancer
Baek MH, et al. J Gynecol Oncol. 2024 May;35:e105. https://doi.org/10.3802/jgo.2024.35.e105
- 1 January 2024
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 35 (6)
Open AccessPrevalence and prognostic value of PD-L1 expression and tumor mutational burden in persistent, recurrent, or metastatic cervical cancer
Baek MH, et al. J Gynecol Oncol. 2024 May;35:e105. https://doi.org/10.3802/jgo.2024.35.e105